文献速递免疫规划卫生政策与健康促进

联邦零售药房计划对二价mRNA新冠疫苗接种的社会人口学特征贡献——美国,2022年9月1日至2023年9月30日

Federal Retail Pharmacy Program Contributions to Bivalent mRNA COVID-19 Vaccinations Across Sociodemographic Characteristics - United States, September 1, 2022-September 30, 2023.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2024-04-04

为评估联邦零售药房计划(FRPP)在不同社会人口学群体中对疫苗接种的贡献,分析了2022年9月1日至2023年9月30日期间二价mRNA新冠疫苗接种数据。

要点

  • FRPP合作伙伴接种了美国约三分之二的二价新冠疫苗剂量(67.7%)。
  • FRPP接种比例随年龄变化,6月龄-4岁儿童为5.9%,18-49岁成人为70.6%。
  • 部分少数族裔群体中≥45%的二价疫苗由FRPP接种,城市和农村分别为81.6%和60.0%。

核心结论

  • FRPP合作伙伴接种了美国约三分之二的二价新冠疫苗剂量,为广泛社会人口学群体提供了疫苗可及性,表明该计划可作为满足常规疫苗和公共卫生紧急事件中卫生服务需求的模型。

研究设计与样本

  • 评估FRPP对疫苗接种贡献的研究,数据来源包括FRPP直接报告至CDC的数据和 jurisdictional immunization information systems 报告至CDC的数据,覆盖所有50个州、哥伦比亚特区、美国领地和自由联系邦,分析2022年9月1日至2023年9月30日期间接种的二价mRNA新冠疫苗剂量。

主要发现

  • FRPP合作伙伴接种的二价疫苗比例从6月龄至4岁儿童的5.9%到18-49岁成人的70.6%不等。
  • 部分种族和族裔少数群体(如西班牙裔或拉丁裔、非西班牙裔黑人或非裔美国人、非西班牙裔夏威夷原住民或其他太平洋岛民、非西班牙裔亚洲人)中,≥45%的二价新冠疫苗剂量由FRPP合作伙伴接种。
  • 在城市和农村地区,FRPP合作伙伴分别接种了81.6%和60.0%的二价疫苗剂量。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Federal Retail Pharmacy Program (FRPP) facilitated integration of pharmacies as partners in national efforts to scale up vaccination capacity during the COVID-19 pandemic emergency response. To evaluate FRPP's contribution to vaccination efforts across various sociodemographic groups, data on COVID-19 bivalent mRNA vaccine doses administered during September 1, 2022-September 30, 2023, were evaluated from two sources: 1) FRPP data reported directly to CDC and 2) jurisdictional immunization information systems data reported to CDC from all 50 states, the District of Columbia, U.S. territories, and freely associated states. Among 59.8 million COVID-19 bivalent vaccine doses administered in the United States during this period, 40.5 million (67.7%) were administered by FRPP partners. The proportion of COVID-19 bivalent doses administered by FRPP partners ranged from 5.9% among children aged 6 months-4 years to 70.6% among adults aged 18-49 years. Among some racial and ethnic minority groups (e.g., Hispanic or Latino, non-Hispanic Black or African American, non-Hispanic Native Hawaiian or other Pacific Islander, and non-Hispanic Asian persons), ≥45% of COVID-19 bivalent vaccine doses were administered by FRPP partners. Further, in urban and rural areas, FRPP partners administered 81.6% and 60.0% of bivalent vaccine doses, respectively. The FRPP partnership administered approximately two thirds of all bivalent COVID-19 vaccine doses in the United States and provided vaccine access for persons across a wide range of sociodemographic groups, demonstrating that this program could serve as a model to address vaccination services needs for routine vaccines and to provide health services in other public health emergencies.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. El Kalach R, Jones-Jack N, Elam MA, et al. Federal Retail Pharmacy Program Contributions to Bivalent mRNA COVID-19 Vaccinations Across Sociodemographic Characteristics - United States, September 1, 2022-September 30, 2023. MMWR Morb Mortal Wkly Rep. 2024. PMID: 38573866. doi:10.15585/mmwr.mm7313a2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。